Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054147" target="_blank" >RIV/00216224:14110/11:00054147 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/11:10582 RIV/65269705:_____/11:#0001341

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >http://dx.doi.org/10.1097/MEG.0b013e32834b326b</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >10.1097/MEG.0b013e32834b326b</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Popis výsledku v původním jazyce

Objective Assess the safety and efficacy of 24 or 48 weeks of treatment with peginterferon alpha-2a (40KD) plus ribavirin in treatment-naive patients with chronic hepatitis C. Methods All patients in this open-label multinational study were assigned at the investigator's discretion to receive peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. Results A total of 789 treatment-naive patients were enroled, of whom 91% (138 of 152) of nongenotype 1 patients and 77% (490 of 637) of genotype 1 patients completed 24 and 48 weeks of treatment, respectively. The overall SVR rate was 58% (459 of 789), and was 70 and 55% in nongenotype 1 and genotype 1 patients, res

Název v anglickém jazyce

Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Popis výsledku anglicky

Objective Assess the safety and efficacy of 24 or 48 weeks of treatment with peginterferon alpha-2a (40KD) plus ribavirin in treatment-naive patients with chronic hepatitis C. Methods All patients in this open-label multinational study were assigned at the investigator's discretion to receive peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon alpha-2a (40KD) 180 mu g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. Results A total of 789 treatment-naive patients were enroled, of whom 91% (138 of 152) of nongenotype 1 patients and 77% (490 of 637) of genotype 1 patients completed 24 and 48 weeks of treatment, respectively. The overall SVR rate was 58% (459 of 789), and was 70 and 55% in nongenotype 1 and genotype 1 patients, res

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Gastroenterology and Hepatology

ISSN

0954-691X

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1004-1010

Kód UT WoS článku

000295831900006

EID výsledku v databázi Scopus

—